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 Introduction 
 With age, the prevalence of death due to chronic dis-
eases increases steeply. Most deaths are due to cardiovas-
cular diseases, with a prevalence of up to 50% in the 
growing elderly population [Euro Heart Survey, Cardio-
vascular Diseases in Europe 2006; http://www.escardio.
org/guidelines-surveys/ehs/Documents/EHS-CVD-re-
port-2006.pdf]. The burden of cost related to these dis-
eases will increasingly challenge public health systems. 
Therefore, diagnostic biomarkers have a great potential 
for the early diagnosis, monitoring and prognosis of a va-
riety of chronic diseases.
 Classical approaches for biomarker discovery are hy-
pothesis-driven, thus related to extensive biochemical re-
search to understand pathological processes and to in-
dentify possible candidate markers. In contrast, technical 
advances over the last decades, especially in mass spec-
trometry (MS) and computation, have allowed a para-
digm shift into the direction of multi-parametric ‘omic’ 
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approaches for biomarker discovery. All classes of bio-
logical compounds, from genes, over mRNA to proteins 
and metabolites, can be analyzed by the respective omic 
approaches, namely genomics, transcriptomics, prote-
omics or metabolomics. The number of genes is around 
20,000 compared to 1,000,000 estimated proteins and 
roughly 5,000 metabolites  [1] . While the data obtained 
from genomics may explain the disposition of diseases, 
e.g., increased risk of acquiring a certain disease, several 
other environmental, not gene-mediated mechanisms 
may be involved in the onset of diseases. Furthermore, a 
single gene can be processed to result in several different 
mRNAs or proteins, which directly determine different 
cellular functions. Changes in metabolite fluxes, as a 
downstream result of gene expression and protein trans-
lation, are expected to be amplified relative to changes in 
the transcriptome and proteome. However, these fluxes 
vary quickly and imply that time-dependent measure-
ments and considerations of metabolite content only at a 
certain time point can be misleading  [2] . It may be appro-
priate to conclude that genomics enables assessing all po-
tential information, proteomics enables assessing the ac-
tually executed programs, and metabolomics will mostly 
display the results of such execution. Therefore, a broad-
er view of the pathology of diseases is likely to be achieved 
using a proteomic approach.
 The analysis of the human proteome has made consid-
erable advances in the last years and is prepared to over-
come several obstacles for its routine application. Of ut-
most consideration is the source of material to be used. 
We will therefore review the different sources of samples 
used for clinically oriented analysis, and attempt to high-
light the different challenges and approaches associated 
with these. Additionally, we want to shortly describe the 
main technological approaches taken, their advantages 
and disadvantages.
 Given the high biological variability as a serious meth-
odological impediment, it appears imperative to evaluate 
clinical conditions not on the basis of single peptide 
markers, but rather on the basis of a panel of biomarkers 
derived from distinct and clearly defined molecules. A 
panel of biomarkers will tolerate changes in individual 
analytes without jeopardizing the diagnostic precision, 
i.e., such variability will not result in gross changes of the 
diagnostic result.
 A major challenge of proteome analysis – as of most 
other multiple parametric tests – is the statistical evalua-
tion of datasets and combinations of single markers to 
specific biomarker models. However, the high number of 
variables also implies an enormous potential benefit: 
multiple (patho-)physiological conditions can be assessed 
based on a single analysis, provided the indicative bio-
markers for these different conditions are known and can 
be analyzed with sufficient accuracy.
 We give several examples on the successful application 
of proteome analysis in the detection of chronic diseases, 
such as diabetes, diabetic nephropathy, coronary artery 
disease (CAD), or highly prevalent malignancies. In ad-
dition, evaluation of therapeutic approaches and progno-
sis of disease progression have recently been demonstrat-
ed.
 Biological Samples 
 For clinical proteomics, the careful selection of sample 
material is of utmost importance. In principle, tissues 
and body fluids and also cell cultures can be analyzed. 
Certainly, tissue samples are closely associated with path-
ological changes, and improvements in the field of laser 
capture microdissection allow sampling of homogenous 
tissue cell populations, but tissue sampling is always re-
lated to invasive procedures. In contrast, the access to 
many body fluids is minimally or non-invasive.
 In general, polypeptides of biological samples are ex-
posed to proteolytic activity and are therefore prone to 
degrade. For example, a detailed evaluation of the ana-
lytical stability of blood serum revealed high proteolytic 
activity activated immediately upon clotting, resulting
in fast degradation and generation of proteolytic prod-
ucts. Consequently, the Human Proteome Consortium 
(HUPO) recommends analyzing blood in the form of 
plasma rather than serum and has established a stan-
dardized sample collection protocol  [3] . Although pro-
teolytic activity in blood plasma is low compared to blood 
serum, considerable residual activity endangering reli-
able proteome analysis can be observed [Muhlen et al., 
manuscript in press]. In contrast, urinary proteins were 
demonstrated to be stable enough for reliable proteome 
analysis  [4, 5] . In this context, the systematic work of 
Fiedler et al.  [6] demonstrated the various influences of 
endogenous and exogenous variables on urine peptide 
patterns, such as urine sampling conditions, urine stor-
age, freeze-thaw cycles and blood/bacterial interferences. 
To minimize these biases, standardized protocols for 
urine sampling and handling are proposed  [7] and should 
be mandatory for other types of biological samples, espe-
cially as those are of generally much larger variability 
than urine.
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 A crude unprocessed biological sample can be consid-
ered an ideal source for a proteomic profiling experiment 
avoiding any artifact or bias arising from sample prepara-
tion. Unfortunately, the presence of interfering com-
pounds, such as aggregates, lipids, carbohydrates, etc., 
often prevent such an approach or let it often appear as 
impractical. Consequently, sample preparation protocols 
should be tested for minimal or at least reproducible loss 
of polypeptides. Reproducibility of sample preparation is 
one of the most important considerations and cannot be 
overemphasized. Each additional step during prepara-
tion introduces additional artifacts to the complex sys-
tem. Hence, it appears advisable to remove biological ma-
trix and other low-molecular weight compounds in a sin-
gle step.
 Technical Considerations 
 Even exactly defined proteomes are highly complex 
mixtures preventing their analysis in a single MS step. 
Therefore, an additional separation step before applying 
MS analysis (pre-MS separation) has to be introduced to 
increase overall analytical resolution. Here, conventional 
separation techniques, such as liquid chromatography 
(LC) or capillary electrophoresis (CE), are followed by 
subsequent MS analysis. A detailed overview into the dif-
ferent ionization processes and into modern mass spec-
trometers would be far beyond the scope of this review 
[for more detailed information, see  8, 9 ]. Briefly, ioniza-
tion of polypeptides as a whole (without its disassem-
bling) in a so-called soft ionization process can techni-
cally be achieved using either matrix-assisted laser de-
sorption ionization (MALDI) or electrospray ionization 
(ESI).
 For MALDI, the sample is mixed with a matrix and 
spotted onto a target plate for co-crystallization. A pulsed 
laser beam desorbs analytes, whereas the matrix mole-
cules absorb the energy of the laser and transfer it to the 
analyte. For proteomic applications, an entire LC or CE 
separation run is spotted offline (without physical con-
nection to the MS) onto the target plate, and subsequent-
ly MS analysis is performed. Offline coupling is techni-
cally less demanding, but tends to ‘signal suppression’, an 
effect observed when certain analytes are preferentially 
ionized and hence are easily detected, but at the expense 
of other analytes that may even become undetectable 
 [10] .
 Pre-MS separation can also be coupled online (with 
physical connection) to MS devices as is generally done 
with ESI, which generates charged droplets in a high-
voltage field. In this field, droplet solvent progressively 
evaporates, generating multiply charged analyte ions. 
This approach may be less stable compared to MALDI 
due to possible electrospray collapses, but is less suscep-
tible to signal suppression effects.
 Besides profiling of biological samples, determination 
of peptide sequences of candidate biomarkers is possible 
as well by using MS approaches ( fig. 1 ). Here, two MS-de-
vices are physically connected to each other (therefore 
tandem MS or MS/MS). The first MS filters or isolates the 
ions of interest (so-called ‘parent ions’). In a second step, 
the isolated parent ions are subjected to fragmentation by 
either collision with other molecules (collision-induced 
dissociation) or by the transfer of electrons to the target 
molecule (electron transfer dissociation). The obtained 
fragments (so-called ‘daughter ions’) are analyzed using 
the second MS instrument ( fig. 1 ). The obtained MS/MS 
spectrum of the fragments displays the sequence of the 
parent ion, which is routinely searched against databases 
to identify the protein from which the biomarker origi-
nated.
 Proteomics Platforms 
 Over the last decades, mainly five different proteomic 
technology platforms were applied, namely two-dimen-
sional gel electrophoresis (2DE), surface-enhanced laser 
desorption/ionization (SELDI), LC-MS, CE coupled to 
MS (CE-MS), and protein arrays ( fig. 2 ). In the following 
section, the different platforms will be introduced and 
their advantages and disadvantages will be discussed 
briefly.
 2DE separates proteins ( 1 10 kDa) according to their 
isoelectric point and molecular mass (Da). Protein iden-
tification is routinely performed in a step-by-step ap-
proach based on proteolytic in-gel digest, followed by gel 
extraction, and MS analysis of the resultant peptide frag-
ments  [11] . In order to reduce gel-to-gel variability and to 
increase the reliability of protein quantification, two-di-
mensional difference gel electrophoresis (2D-DIGE) was 
developed. The method utilizes two samples differential-
ly labeled with fluorescent dyes (e.g. Cy3 and Cy5). Sub-
sequently, the two samples are resolved simultaneously 
within the same gel. While the approach allows satisfac-
tory comparison of two samples  [12] , the comparison of 
several different experiments remains challenging. In 
summary, 2DE provides high resolution protein separa-
tion and direct information on expression levels of intact 
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proteins. Methodologically, 2DE is rather time-consum-
ing, due to a certain extent to the lack of automation, and 
inter-assay comparability is difficult to achieve  [13] . How-
ever, 2DE still appears to be the method of choice for 
comparative analysis of large proteins.
 SELDI attempted to resolve several limitations of 2DE-
MS and was applied in a number of clinically relevant 
proteome investigations. SELDI utilizes selective interac-
tions of polypeptides with different chip surfaces to 
achieve fractionation of biological samples and thereby to 
reduce their complexity for subsequent MALDI-MS anal-
ysis. Numerous matrices serve as ‘active’ surfaces, such as 
hydrophilic material, reversed-phase material, or affinity 
reagents, such as lectins or antibodies. The aim is to bind 
a small, but well-defined fraction to the surface, depend-
ing on the concentration, pH, salt content, presence of 
interfering compounds like lipids, etc. Unfortunately, ex-
actly this core element represents SELDI’s major analyti-
cal obstacle: reproducibility of binding appears to be low 
and the inability to detect low abundance peptides and 
proteins – in part due to the limited resolution of the ap-
plied mass spectrometer – as well as the inability to di-
rectly identify discriminatory peaks are major draw-
backs. Currently, efforts are underway to alleviate at least 
some of the reproducibility issues by strict technical con-
trol  [14] , by the use of higher resolution mass spectrom-
eters, and alternative sample preparation and pre-frac-
tionation strategies  [15] . Recently, material-enhanced la-
ser desorption/ionization (MELDI) was introduced to 
handle the low reproducibility of binding to SELDI sur-
faces by utilizing various functionalized porous carrier 
materials with enlarged active binding surfaces  [16] .
 If analytical sensitivity is being considered, LC-MS 
provides high-resolution separation with a high capacity 
MS:
MS/MS:
ESI
or
Laser
MALDI
ESI
or
Laser
MALDI
MS1 MS2Fragmentation
cell
Argon
gas
Detector
MASS
SEQUENCE
 Fig. 1. Tandem mass spectrometry for peptide sequencing. Mass 
spectrometric (MS) approaches are suitable to determine the pep-
tide sequences of candidate biomarkers. The upper panel sche-
matically depicts classical MS analysis of analytes. Ionization is 
either achieved by electrospray ionization (ESI) or matrix-assisted 
laser desorption/ionization (MALDI). The mass of analytes is de-
termined and displayed in the mass spectrum (upper right panel). 
For peptide sequencing, two MS devices are physically connected 
to each other (lower panel). The first MS filters or isolates the ions 
of interest (so-called ‘parent ions’). In a second step, the isolated 
parent ions are subjected to fragmentation by either collision with 
other molecules (collision-induced dissociation) or by the trans-
fer of electrons to the target molecule (electron transfer dissocia-
tion). The obtained fragments (so-called ‘daughter ions’) are ana-
lyzed using the second MS instrument. The obtained MS/MS 
spectrum of the fragments (lower right panel) displays sequence 
of the parent ion, which is routinely searched against databases to 
identify the protein from which the biomarker originated. 
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for analytes that can be loaded onto an LC column [for a 
more in-depth review, see  17] . To deepen analysis, se-
quential separation with different matrices can be per-
formed in two independent steps. Approaches like mul-
tidimensional protein identification technology  [18] and 
2D liquid phase fractionation  [19] provide immense 
amounts of data. Generally, LC-MS tends to be time-con-
suming, hence limiting its application in routine clinical 
analysis. Additionally, LC is sensitive towards interfering 
compounds and precipitation of analytes on column ma-
terials  [13] , complicating separation of large analytes cov-
ering broad ranges of hydrophobicity. In the last decade, 
monoliths were applied in mircoscale chromatographic 
separation, such as   -LC-MS  [20] , to tackle these limita-
tions due to easy column preparation, fritless design, 
high permeability, low backpressure, fast analyte mass 
transfer, and versatile surface chemistry  [21] .
 In contrast, CE-MS used free-flow separation of ana-
lytes in buffer-filled capillaries  [22] . Therefore, CE-MS is 
relatively robust and compatible with almost all kinds of 
volatile buffers without continuous adjustment of the 
ionization voltage for optimal ESI  [23] , due to the absence 
Protein array
Sample
Laser
2-DE-MS
LC-MS
SELDI
CE-MS
One sample
(many peptides)
Capillary electrophoresis
TOF mass spectrometer
Separation
Ionization
Measurement
 Fig. 2. Proteomics platforms. Mainly five different proteomic 
technology platforms are routinely applied: two-dimensional gel 
electrophoresis (2DE), surface-enhanced laser desorption/ioniza-
tion (SELDI), liquid chromatography mass spectrometry (LC-
MS), capillary electrophoresis coupled to mass spectrometry (CE-
MS), and protein arrays. 2DE separates proteins ( 1 10 kDa) ac-
cording to their isoelectric point (pI) and molecular mass (Da). 
SELDI utilizes selective interactions of polypeptides with differ-
ent chip surfaces to achieve fractionation of biological samples. 
LC-MS provides high-resolution separation with a high capacity 
for analytes. CE-MS is relatively robust and compatible with
almost all kinds of volatile buffers. Protein microarrays detect 
specific proteins in a non-MS-based ‘targeted proteomics’ ap-
proach. 
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of buffer gradients, as is the case in LC-coupled MS anal-
ysis. Therefore, CE-MS certainly appears to be an excel-
lent choice for the fast high resolution analysis of complex 
biological samples. However, CE-MS is not well suited for 
the analysis of proteins of  1 20–30 kDa due to at least par-
tial precipitation of these proteins when acidic running 
buffers are used, as is frequently the case. The problem 
can be addressed by depletion of those analytes using ul-
trafiltration  [24] .
 In contrast to the already discussed platforms, protein 
microarrays detect specific proteins in a non-MS-based 
‘targeted proteomics’ approach. The technique prints 
specific antibodies or antigens on a slide or a membrane 
to facilitate immune detection of multiple proteins. A sin-
gle sample is hybridized to the array followed by the de-
tection of the captured antigens or antibodies  [25] . How-
ever, not only the demand for target peptide sequence in-
formation and a highly specific probe for every target 
molecule (in contrast to nucleic acid arrays, no anti-sense 
sequence can be used) restricts broad applicability, but 
the low density also limits detection to a small set of pro-
teins without addressing post-translational modifica-
tions  [25] .
 Processing of Proteomic Data 
 Proteomic biomarker discovery can be considered a 
sophisticated search for a needle in a haystack. The im-
mense data of a single proteomic analysis require ade-
quate tools for data analysis. The essentials to be extract-
ed are identity and quantity of detected polypeptides. 
Therefore, protein quantification is of essential relevance. 
For gels, protein stains, such as Coomassie blue or silver 
stains, are routinely used for quantification. More recent-
ly, fluorescent dyes provide larger linear dynamic ranges 
in combination with similar or better sensitivity  [26] . For 
MS-based proteomics, relative quantification based on 
ion counting is available, demanding care in instrument 
and technical consistency  [27] . Absolute quantification is 
usually achieved using an isotope-labeled marker analog. 
The need for prior successful identification of a target se-
quence and/or its chemical derivatization is certainly re-
strictive. Generally, relative quantification with reference 
to constant peaks appears sufficient, especially consider-
ing given biological variation [Jantos-Siwy et al., manu-
script in press].
 For comparative data evaluation, it is essential to be 
able to identify identical polypeptides with high proba-
bility in consecutive samples. Hence, the resolution and 
accuracy of the parameters used for target definition are 
of major importance, such as retention time for LC sepa-
ration, migration time for CE separation, and molecular 
mass. Separation-based parameters often vary with the 
ion content of the samples, pinpointing the need for thor-
ough data normalization. While mass deviations or dif-
ferences in retention time face analytical variances, sig-
nal intensities of analytes depend on both analytical vari-
ances, such as signal suppression, and pre-analytical 
variances, such as dilution of a urine samples by different 
hydration states of donors. Therefore, normalization has 
to compensate for deviations in all three dimensions of 
data, the two defining parameters, e.g. retention time and 
molecular weight, in addition to signal intensity. Ade-
quate approaches have been developed using either exter-
nal standards or polypeptides that are found with high 
frequency in the analyzed samples and that serve as in-
ternal standards  [24] .
 Statistical data mining when dealing with biological 
samples is often related to the special situation that the 
number of variables (polypeptides) highly outnumbers 
that of available samples. This generally results in a high-
er dimension of mathematical problems, and the selec-
tion of significant items has to consider respective adjust-
ments for multiple hypothesis testing. Particularly, glob-
al procedures or adjustment of the p values, e.g. using 
classical Bonferroni correction, should be mandatory.
 Bioinformatic Approaches in Proteomics 
 Medical definitions of diseases are often generic de-
scriptions of observed symptoms and less is known about 
the exact pathological processes involved. Consequently, 
the concept of a single biomarker, allowing not only reli-
able diagnosis but also staging and prognosis, appears 
questionable. Combining multiple independent biomark-
ers to a diagnostic or predictive pattern may be adequate 
to address this problem. Many algorithms have emerged 
utilizing the available information on multiple biomark-
ers  [28] with hierarchical decision tree-based classifica-
tion methods  [29] , support vector machines  [30] , or 
Gaussian process  [31] among them. A detailed discussion 
of the advantages and disadvantages of certain classifica-
tion algorithms is beyond the scope of this review [for 
more detailed information, see  28] . Generally, every ap-
proach applied to a given classification problem should 
consider keeping the number of independent variables 
minimal and certainly below the number of datasets in-
vestigated. Under such circumstances, over-fitting or 
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‘memorizing’ to the training set and thus poor classifica-
tion of blinded datasets can be minimized. Independent 
of the algorithm applied, the generated classifiers should 
be imperatively validated using a blinded dataset in any 
report on potential biomarkers to exclude any memoriz-
ing and to quantify diagnostic performance  [7] .
 Aging 
 The former sections tried to give a concise overview 
about the technical aspects of proteomics. The following 
sections will describe the application of these methods to 
questions on age-related chronic diseases. In this review, 
we will present some examples demonstrating general 
principles or potential future developments in the field of 
clinical proteomics, regarding diseases related to aging. 
We will start with the process of aging itself and go on 
with widespread diseases, such as diabetes, CAD, and 
different types of cancers ( fig. 3 ).
 Aging can be understood as a multidimensional pro-
cess in an organism of physical, psychological, and social 
change over time. Some dimensions of aging grow and 
expand over time (e.g. knowledge of world events or ex-
perience), while others decline, such as proliferative ca-
pacity of cells or glomerular filtration rate of the kidney. 
Since the very first clinical observation of kidney diseas-
es, it has been suspected that the urinary protein content 
can reflect the pathological changes in the kidney. There-
fore, detailed analysis of the urinary proteome might also 
be informative on the physiological changes in the aging 
kidney. However, detailed high resolution analysis of uri-
nary proteins and peptides has only recently become pos-
sible. We analyzed the low molecular weight urinary pro-
teome of 324 healthy individuals from 2 to 73 years of age 
to gain insight into renal aging in humans. We observed 
age-related modification of expression in 325 of 5,000 
urinary peptides. The majority of these changes was as-
sociated with renal development before and during pu-
berty, while 49 peptides were related to aging in adults. 
Of these 49 peptides, the majority was also a marker of 
chronic kidney disease, suggesting high similarity be-
tween aging and chronic renal disease. The identification 
of a number of these age-related peptides as urinary frag-
ments of collagen   1 type I suggests that modified pro-
teolytic activity is involved in human renal ageing. These 
observations are in line with the main histological obser-
vations that the decline in glomerular filtration rate in 
the aging population is accompanied by glomerular scle-
rosis and increases in interstitial tissue, i.e. expansion of 
the extracellular matrix (ECM). Under physiological 
conditions, the ECM is thought to be maintained by equi-
librium of synthesis and degradation. We observed that 
age modifies the occurrence of a number of urinary frag-
ments of collagen   1 type I representing the proteolytic 
activity in the kidney  [28] . We propose that the decrease 
in urinary collagen type I fragments with increasing age 
reflects a decrease in the activity of the renal proteolytic 
enzymes that is accompanied by increased renal ECM ac-
cumulation in the elderly and a reduction in urinary col-
lagen type I fragments. This work pinpoints the role of 
synthetic and degradative processes in modulating cell 
machinery and emphasizes metabolic impairment with 
age.
 In humans, telomere shortening occurs in the vast ma-
jority of tissues during physiological aging and is acceler-
ated in chronic diseases that increase the rate of cell turn-
over. Therefore, telomere dysfunction limits the prolif-
erative capacity of human cells by activation of DNA 
damage responses, inducing senescence or apoptosis. Re-
cently, CRAMP, stathmin, EF-1, and chitinase were iden-
tified as marker proteins that are secreted from telomere-
dysfunctional bone marrow cells of late generation telo-
merase knockout mice (G4mTerc–/–)  [32] . The expression 
levels of these proteins increase in blood and in various 
tissues of aging G4mTerc–/– mice, but not in aging mice 
with long telomere reserves. Orthologs of these proteins 
are upregulated in late passage presenescent human fi-
broblasts and in early passage human cells in response to 
DNA-damaging   -irradiation. In a blinded study, the ex-
pression levels of these marker proteins were validated to 
increase in blood plasma of aging humans and to show 
further increase in geriatric patients with aging-associ-
ated diseases. Moreover, there was a significant increase 
in the expression of these biomarkers in the blood plasma 
of patients with chronic diseases that are associated with 
increased rates of cell turnover and telomere shortening, 
such as cirrhosis and myelodysplastic syndromes. These 
results support the concept that telomere dysfunction 
and DNA damage are interconnected pathways that are 
activated during human aging and disease. Furthermore, 
both telomere dysfunction and DNA damage may gener-
ate subsequent errors in the fidelity of protein synthesis 
according to the popular ‘error catastrophe’ theory of ag-
ing  [33] , proposing age-accumulating damage and cellu-
lar morphology changes. Therefore, it is important to un-
derstand and detect changes in physiological function 
and structure that normally occur with aging, and to dis-
tinguish these changes from alterations that take place 
with disease.
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 Diabetic Nephropathy 
 Long-standing diabetes is associated with a decline in 
renal function, and diabetic nephropathy has become the 
most prevalent cause of end-stage renal disease. Over the 
years, efforts have been made to find biomarkers early in 
the clinical course to better identify and treat individuals 
at high risk of diabetic nephropathy.
 Sharma et al.  [34] used 2D-DIGE to identify   1-anti-
trypsin as a potentially upregulated marker in 3 patients 
with diabetic nephropathy. This study also underlines 
the limitations of 2DE; only a few samples and controls 
could be analyzed with reasonable effort. Nevertheless, it 
becomes evident that such an approach will be essential 
to develop a strategy for the definition and validation of 
several potential biomarkers in the future.
Diabetic
nephropathy
Cardiovascular
disease
Urogenital
cancers
Breast
cancer
 Fig. 3. Chronic age-related diseases. Age-related changes in the 
proteome have been described and were found to be highly simi-
lar to changes associated with chronic diseases. We give several 
examples on the successful application of proteomics in the diag-
nosis, prognosis and therapy of these chronic diseases. Long-
standing diabetes is associated with a decline in renal function 
and diabetic nephropathy has become the most prevalent cause of 
end-stage renal disease (1). Patients with type 2 diabetes particu-
larly progress to severe life-threatening coronary artery disease, 
the leading cause of morbidity and mortality worldwide (2). Can-
cer can be considered a chronic disease predominately observed 
in the second half of life. Taken together, urological tumors of the 
prostate (3) and the bladder (4) are the most incident malignancies 
in the United States followed by breast cancer (5), and cause more 
than 35% of incidences. Essentially, all clinical proteomic investi-
gations indicate that the approach to combine several disease-as-
sociated markers to a clearly distinct panel appears to be well suit-
ed for disease diagnosis, staging, progression, and for assessment 
of prognosis of these chronic diseases. 
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 Analysis of the urinary proteome in patients with type 
2 diabetes mellitus using CE-MS revealed 168 urinary 
proteins present in over 90% of the samples, suggesting 
the existence of a consistent urinary proteome  [35] . Sev-
eral independent proteomic studies using 2DE or LC-MS 
support this hypothesis with the establishment of uri-
nary proteome databases  [36–38] . Biomarker patterns en-
abled not only the diagnosis of a specific (primary) kid-
ney disease, but also the differential diagnosis with high 
sensitivity and specificity for the different kidney diseas-
es, such as IgA nephropathy, focal-segmental glomerulo-
sclerosis, membranous glomerulonephritis, minimal-
change disease, and diabetic nephropathy. These find-
ings have recently been validated in blinded, partially 
prospective clinical studies  [39–41] .
 Interestingly, many of the identified discriminatory 
urinary polypeptides of patients with renal diseases are 
proteolytic fragments of larger proteins. These findings 
suggest that specific proteases in urine may cleave these 
excreted proteins as supported by a recent study of pa-
tients with nephrotic syndrome due to different glomeru-
lar diseases. The findings demonstrate specific urinary 
proteases that cleaved albumin and   1-antitrypsin. Al-
most 100 proteolytic fragments appeared as distinct spots 
on 2D gels  [42] .
 Urinary proteome analysis may also be an excellent 
tool for fast, noninvasive, and unbiased monitoring of 
disease progression or response to therapy. In a random-
ized double-blinded placebo-controlled study, the treat-
ment of macroalbuminuric patients was evaluated with 
daily doses of 8, 16, 32 mg candesartan or placebo for 2 
months  [43] . Treatment with candesartan was signifi-
cantly displayed in 15 of 113 proteins characteristic for 
diabetic nephropathy. Data from patients with vasculitis, 
where therapy improved or changed the vasculitis-spe-
cific protein pattern towards a normal urinary proteome, 
outline the potential of proteomic approaches in therapy 
monitoring [Haubitz et al., submitted;  42 ].
 Coronary Artery Disease 
 Although CAD is a leading cause of morbidity and 
mortality worldwide and risk factors (dyslipidemia, dia-
betes, hypertension) and humoral markers of plaque 
vulnerability (C-reactive protein, interleukin-6, -10 and 
-18, CD-40L) have been identified, there is still little 
known about the underlying molecular causes. Certain 
subgroups of patients, such as patients with type 2 dia-
betes and the elderly, particularly progress to severe life-
threatening CAD without many symptoms and signs 
 [44] .
 Several groups have reported on the application of 
mainly 2DE proteomic techniques to analyze tissue or 
plaque specimens to study cardiovascular disease or ar-
teriosclerosis. For instance, the protein expression profile 
of atherosclerotic tissue samples revealed 39 differential-
ly expressed proteins  [45] . These are involved in a number 
of biological processes, including calcium-mediated pro-
cesses, migration of vascular smooth muscle cells, matrix 
metalloproteinase activation and regulation of proin-
flammatory cytokines. Confirmation of differential pro-
tein expression was performed by Western blot analysis. 
Additionally, the ferritin light chain was differentially ex-
pressed in 10 coronary arteries from patients with CAD 
compared to 7 vessels from healthy individuals. These 
results were subsequently confirmed by Western blot and 
quantitative real-time PCR analysis  [46] . The authors 
concluded that increased expression of the ferritin light 
chain in diseased coronary arteries may be related to in-
creased protein stability or upregulation of expression at 
the posttranscriptional level in the diseased tissues. Du-
ran et al.  [47] applied 2DE to carotid atherosclerotic 
plaques cultured in vitro. A comparison of the diseased 
vessel with normal controls revealed differential patterns 
of protein secretion  [47] .
 Vaisar et al.  [48] used LC-MS/MS shotgun proteomics 
to profile HDL composition. They compared isolates 
from healthy subjects and subjects with CAD and identi-
fied multiple complement-regulatory proteins and a pat-
tern of serpins with serine-type endopeptidase inhibitor 
activity. Many acute-phase response proteins were also 
detected, supporting the proposal that HDL cholesterol 
is of central importance in inflammation  [48] .
 All the above-mentioned studies did not yield novel 
diagnostic or prognostic biomarkers of CAD. Only a few 
studies focused on the analysis of body fluids derived 
through minimally invasive means. However, these stud-
ies were either based on pooled blood specimens  [47, 48] , 
making individual sample classification impossible, or 
they included only small patient cohorts without blinded 
studies for validation  [48] .
 Recently, 370 urine samples from 88 patients with se-
vere CAD and 282 controls were analyzed using CE-MS 
 [49] . The ability of a CAD-specific pattern of 15 peptides 
to predict the presence of CAD was evaluated in a blind-
ed study. The signature panel showed a sensitivity of 98% 
and a specificity of 83% in discriminating between the 
presence and absence of disease. Using peptide sequenc-
ing (top-down MS/MS approach), five of the polypep-
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tides constituting the CAD-specific panel were identified 
as fragments of collagen   -1 type I or III. These types of 
collagens are predominant proteins in the arterial walls 
and also appear together in the thickened intima of ath-
erosclerotic lesions. The observation that all identified 
collagen fragments were upregulated in CAD samples 
compared to controls suggests that the elevated collagen 
degradation levels are related to increased collagenase ac-
tivity. Interestingly, increased MMP-9 collagenase levels 
have been reported in patients with stable angiographic 
coronary atherosclerosis  [50] . The established pattern 
demonstrated a response to exercise therapy. While pre-
dominantly inactive patients had no change in pattern. 
Physically active patients showed significant changes to-
wards a ‘healthier’ biomarker pattern over 14 weeks, sug-
gesting the possibility of measuring the effects of thera-
peutic interventions to assist personalized medicine 
strategies.
 In a sub-cohort of the Coronary Artery Calcification 
in Type I Diabetes (CACTI) study, the same pattern was 
applied to urine samples from 19 individuals with no his-
tory of CAD at baseline and age-, sex- and diabetes-
matched controls. The CAD score significantly predicted 
development of CAD (OR 2.2; 95% CI 1.3–5.2; p = 0.0016) 
and remained significant when individually corrected for 
common CAD risk factors [Snell-Bergeon et al., in press]. 
These data strongly suggest that urinary proteome pat-
terns can predict future cardiovascular events. Further-
more, this observation also provides a molecular basis for 
the link between the kidney and CAD, and may help to 
explain why chronic kidney disease is one of the best pre-
dictors for CAD  [46] .
 In an independent study, Muhlen et al. [in press] ana-
lyzed urine and plasma samples of patients presenting 
with acute symptoms suspicious for CAD by CE-MS. All 
patients were subjected to coronary angiography and ei-
ther assigned to a CAD or non-CAD group. Significant 
discriminatory power was achieved in urine, but not in 
plasma. The authors concluded that the reproducibility 
of proteomic plasma analysis may be limited by latent 
protease activity. In contrast, a combination of 17 urinary 
polypeptides allowed separation of both groups in a 
blinded study with an accuracy of 84%. Sequencing of 
these discriminatory peptides identified fragments of 
collagen   1 (types I and III), which were furthermore 
demonstrated to be expressed in atherosclerotic plaques 
of the human aorta. These findings independently con-
firmed the observations of Zimmerli et al.  [49] .
 Malignancies 
 Cancer can be considered as a chronic disease pre-
dominately observed in the second half of life. About 25% 
of total deaths per year in the European Union are related 
to tumors. Taken together, prostate cancer (PCa) and 
bladder cancer (BCa) are the malignancies most often 
found in the United States followed by breast cancer. 
These three malignancies together caused more than 35% 
of the cancer incidences in 2007 [http://www.cancer.org/
downloads/STT/EstimatedNewCancerCasesByState-
2007OldMethod.pdf], pinpointing the urgent need for 
novel biomarkers for cancer. In general, the applications 
of proteomic technologies for the discovery of cancer bio-
markers are numerous, and a detailed overview is clearly 
beyond the possibilities of a single review. Therefore, we 
will focus on the three most incident malignancies and 
present examples demonstrating technological principles 
that already have proven clinical relevance.
 Prostate Cancer 
 Since the advent of prostate-specific antigen (PSA) 
screening, a significant number of US men have had a 
PSA test. The screening led to a significant increase in the 
number of cases diagnosed  [51] . Unfortunately, the spec-
ificity of PSA is around 70% and this results in up to 
700,000 unnecessary prostate biopsies per year in the 
United States  [52] . Additionally, it is impossible to distin-
guish clinically relevant PCa from cases requiring no fur-
ther intervention. Therefore, if screening for this disease 
is to continue, then improved novel markers enabling this 
distinction are needed to avoid unnecessary biopsies and 
to recognize patients suitable for therapy.
 It is no surprise that research attempts to integrate the 
potential benefits of novel technologies to address these 
current issues. SELDI profiling of tissue specimens has 
been used for the comparative analysis of laser capture 
microdissection-derived normal matched, high-grade 
prostatic intraepithelial neoplasia (PIN3) and malignant 
tumor cells  [53] . In radical prostatectomy specimens, a 
dimeric form of mature growth factor 15 (GDF15) was 
found to be upregulated in PCa samples compared to 
PIN3 and normal controls. The quantitative proteomic 
profiling of tissue specimens using glycopeptide captur-
ing followed by tandem MS showed tissue metallopro-
teinase inhibitor 1 to be downregulated in PCa  [54] .
 Alternatively to the analysis of tissue specimens and 
their survey for diagnostic purposes, body fluids such as 
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blood can be analyzed. SELDI-derived diagnostic pat-
terns of proteins in human serum for PCa were first re-
ported by Adam et al.  [55] . They detected PCa patients 
with 83% sensitivity and 97% specificity in an indepen-
dent validation set including 60 samples from patients 
with PCa, benign prostatic hyperplasia (BPH) and healthy 
controls. Unfortunately, the results were subsequently 
heavily debated, predominantly because of the techno-
logical limitations of SELDI (see Proteomic Platforms 
section) and the instability of blood serum per se.
 Therefore, the focus of proteomic profiling has some-
what shifted to urine to detect PCa. In first experiments, 
Rehman et al.  [56] analyzed the urine of 6 patients suffer-
ing from PCa and 6 BPH controls after prostate mas-
sage using 2DE mass fingerprinting. Urinary calgranulin 
B/MRP-14 was identified as a potential novel marker for 
PCa.
 M’Koma et al.  [57] introduced a method for discrimi-
nating PCa, PIN3, and BPH by analyzing urine using re-
verse phase adsorption followed by MALDI-MS. Inter-
estingly, the authors were able to discriminate PCa and 
BPH with lower diagnostic accuracy (67% sensitivity and 
71% specificity) than observed for PCa and HGPIN (81% 
sensitivity and 80% specificity), although the PIN3 state 
is histologically very similar to PCa.
 Recently, the application of urinary profiling was de-
scribed using CE online coupled to MS (CE-MS) in the 
noninvasive diagnosis of PCa  [58] . In a blinded prospec-
tive study, a panel of 12 novel biomarkers for PCa (PCaP) 
was identified and validated. PCa-specific biomarkers 
could only be discovered in the first void urine (mid-
stream urine samples did not enable identification of dis-
criminatory molecules), suggesting that prostatic fluids 
may be the source of the defined biomarkers. Conse-
quently, first void urine samples were tested for sufficient 
amounts of prostatic fluid, using a prostatic fluid indica-
tive panel (IPP). A combination of IPP and PCaP to pre-
dict positive prostate biopsy was evaluated in the blinded 
prospective arm of the study. PCa was detected with 89% 
sensitivity and 51% specificity. Including age and percent 
free PSA in the proteomic signatures resulted in 91% sen-
sitivity and 69% specificity.
 This work underlines the importance of standardizing 
urine sampling for biomarker discovery. Thus, the ques-
tions whether to massage, the duration of the massage 
before collecting initial void, or whether to collect a stan-
dard void directly influence the ability to detect a given 
marker (panel) of prostate malignancy.
 Bladder Cancer 
 Although the incidence of BCa is only a quarter of that 
observed for PCa, many patients suffering from bladder 
tumors show tumor recurrence, making BCa one of the 
most prevalent cancers worldwide. Therefore, especially 
screening for recurrence of BCa emphasizes the demand 
for reliable assays for the early detection of BCa recur-
rence once an initial tumor has been removed.
 Using 2DE of urothelial tissue, BCa-specific nuclear 
matrix proteins (BCa antigen or BLCA-1, -4, and -6) have 
been identified  [59–62] . A sandwich immunoassay for 
BLCA-4 in urine discriminated patients with BCa with 
95% specificity and 89% sensitivity  [61] . Validation of 
these findings is currently underway in multicenter clin-
ical trials.
 Rasmussen et al.  [63] extensively studied the urine of 
BCa patients using 2DE and could establish a database of 
339 protein spots; 124 spots have been identified. In the 
following years, the same group successfully applied dif-
ferential tissue profiling using [ 35 S]-methionine labeling 
followed by 2DE-MS and Western blotting to define and 
validate novel biomarkers, such as   -glutathione S-trans-
ferase, prostaglandin dehydrogenase, fatty acid-binding 
protein (FABP), and keratin for BCa diagnosis and tumor 
phenotyping  [64] . In an independent study, FABP levels 
were assessed in 2,317 paraffin-embedded tissue blocks 
and were found to be associated with tumor grade and 
invasiveness  [65] . Iwaki et al.  [66] and Kageyama et al. 
 [67] identified a panel consisting of calreticulin,   -synu-
clein, and catechol-O-methyltransferase in 2DE profiling 
of tissue specimens and applied antibodies against the 
panel in Western blotting of urine. Based on 112 BCa and 
230 controls, sensitivity and specificity of 76.8 and 77.4% 
were obtained. However, a validation of these promising 
findings in a blinded prospective study is missing.
 The diagnostic impact of tissue-derived markers re-
mains directly related to the success of the tissue biopsy. 
Therefore, Vlahou et al.  [68] described multiple transi-
tional cell carcinoma (TCC)-associated protein changes 
in urine investigated using SELDI technology. The com-
bination of these changes allowed BCa detection with a 
sensitivity of 87% and specificity of 66%. One of the TCC 
biomarkers with a molecular weight of 3.4 kDa was iden-
tified as   -defensin. These proteins were also selected as 
TCC classifiers in a study by Munro et al.  [14] , which in-
volved SELDI analysis of urine samples from a total of 
227 BCa patients and controls, and were also found to be 
overexpressed in invasive bladder tumors by immunohis-
tochemistry  [69] . The reported performance of SELDI 
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profiles in detecting BCa in blinded sets of samples range 
from 72–93% sensitivity and 63–87% specificity  [14, 15, 
68, 70–73] . Comparison of the datasets is not easy to 
achieve due to different chip surfaces and conditions 
used in the various studies.
 Using CE-MS, Theodorescu et al.  [5] profiled the urine 
samples of 46 patients with BCa and compared the ob-
tained profiles with those of 33 healthy volunteers and 
366 patients with malignant and non-malignant genito-
urinary diseases. A panel of 22 specific markers was val-
idated in a blinded prospective study including 31 BCa 
patients, 11 healthy individuals, and 138 patients with 
non-malignant genitourinary diseases with a sensitivity 
of 100% and specificity ranging from 86 (nephroliths) to 
100% (healthy controls). Recently, the authors extended 
their approach to the noninvasive staging of BCa, and 
validated a pattern of 4 urinary polypeptides discrimi-
nating superficial tumor stages (pTis, pTa and pT1) from 
muscle-invasive stages (pT2–4) with high accuracy 
[Schiffer et al., manuscript submitted].
 Breast Cancer 
 Breast cancer is the most prevalent malignancy in 
women with good prognosis if diagnosed at an early 
stage. Systematic screening programs have increased the 
survival rate over the last decades. However, many pa-
tients still die from metastatic relapse. Breast cancer is a 
complex disease and many efforts have been made to 
study different types of breast tumors. The most frequent 
type is ductal breast cancer (  80%), while medullary 
breast cancer (MBC) is rarer. Morphological diagnosis 
remains difficult and little is known about features of ag-
gressiveness, proliferation, and molecular alternations 
involved in the disease.
 In the last decade, the application of proteomic meth-
ods to the analysis of breast cancer has primarily focused 
on tissue microarrays [for a more detailed review, see  74] . 
Using microarray technology, Jacquemier et al.  [75] ana-
lyzed 18 proteins, including tumor suppressors, onco-
genes, and proteins, on their clinical significance related 
to the proliferation and differentiation of breast tissue. 
They analyzed 61 MBC and 300 grade 3 non-MBCs and 
characterized MBCs as being highly differentiated in 
basla/myoepithelial phenotype, defined by a logistic re-
gression model including levels of P-cadherin, MIB1/
Ki67, ERBB2, and p53 using tissue microarrays. Using the 
same technique, the authors monitored expression of 26 
selected proteins in more than 1,600 cancer samples from 
552 consecutive patients with breast cancer in early stage 
 [76] . The method identified a prognostic set of 21 pro-
teins, significantly correlated to 5-year metastasis-free 
survival, in a learning set of 368 patients (p  ! 0.0001) and 
in a validation set of 184 patients (p  ! 0.0001).
 Moreira et al.  [77] studied 14-3-3  tumor suppressor 
as a key protein in breast cancer progression. They ana-
lyzed 65 primary breast carcinomas by immunostained 
2DE and validated their findings in an independent set of 
65 tumors using tissue microarrays. Surprisingly, down-
regulation of 14-3-3  was sporadic in breast carcinomas, 
in contrast to the results found for BCa  [78] .
 In order to define diagnostic biomarkers for breast 
cancer, SELDI analysis of blood as either serum or plasma 
was mainly applied  [79–82] with sensitivities and speci-
ficities between 83–93 and 87–93%. However, only Hu et 
al.  [82] validated their findings in an independent test set. 
The majority of these investigations suffer from limited 
patient numbers to sufficiently address the heterogeneity 
of the disease. Taking into account the methodological 
problems of the SELDI technology (see Proteomic Plat-
forms section), these findings should be carefully reeval-
uated to substantiate the hypothesis of serum/plasma 
biomarkers of breast cancer.
 Nipple aspirate fluid is an alternative body fluid more 
directly related to the tumor itself. Therefore, it might be 
seen as a potential source of breast cancer-specific diag-
nostic markers. There are some promising reports on the 
evaluation of the fluid and establishing methods to ex-
ploit the potential diagnostic information  [83–85] .
 Recently, saliva was analyzed for breast cancer tumor 
markers using LC-MS/MS  [86] . Although this body fluid 
is easily accessible and therefore an attractive source of 
biomarkers, the preliminary data have to be thoroughly 
validated in the future.
 Conclusions and Outlook 
 A boost in disease-related proteomic information is 
expected in the very near future, which will also result in 
its broad clinical application. Compared to the high ex-
pectations generated by the more than 25 years of tech-
nological progress, the impact of proteomics on our un-
derstanding of the pathogenesis, diagnosis and treatment 
of diseases is modest, but significant. Essentially, all clin-
ical proteomic investigations indicate that the approach 
to combine several disease-associated markers to a clear-
ly distinct panel appears to be well suited for disease di-
agnosis, staging, progression, and the assessment of prog-
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nosis. However, a thorough validation of these signatures 
in well-designed blinded studies is essential and should 
therefore be mandatory  [7] .
 To date, proteomics is still far from evolving its full 
potential as a tool in routine clinical settings. Neverthe-
less, there are several studies available including a sub-
stantial number of patients that clearly demonstrate its 
potential  [5, 41, 49, 71] . However, to take full advantage of 
the techniques, further standardization is needed to en-
able meta-analysis of datasets from different laboratories 
and a more fundamental knowledge in the context of 
clinically important questions. The Human Urine and 
Kidney Proteome Initiative within HUPO (http://hkupp.
kir.jp) certainly provides invaluable help to this end.
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